Mounjaro is the newer of the injectable products authorised in the EU for weight management, and it works through a different mechanism from the semaglutide-based ones. For residents of the Czech Republic the practical questions are usually three: what it is approved for, who may prescribe it here, and what treatment involves. The answers below come from the regulatory documents, with the risks stated alongside.

What Mounjaro is and what it is approved for

The active substance is tirzepatide, a dual GIP and GLP-1 receptor agonist. It acts on the receptors of two gut hormones that influence satiety, gastric emptying and blood glucose, and it is given as a subcutaneous injection once a week. Its EU authorisation covers two distinct indications (EMA: Mounjaro):

Type 2 diabetes in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise when other treatment is not sufficient.
Weight management in adults with a BMI of 30 or above, or a BMI of 27 to under 30 with at least one weight-related condition, for example high blood pressure, dyslipidaemia, obstructive sleep apnoea, prediabetes or type 2 diabetes.

In both cases it is an adjunct to a reduced-calorie diet and increased physical activity, not a substitute. It is prescription-only; the summary of product characteristics is available through SÚKL.

Who can prescribe it in the Czech Republic

Czech practice differs from one product to another. A few products carry extra national conditions coded into the eRecept system, published individually product by product. For the diabetes product Ozempic, a recorded diagnosis of type 1 or type 2 diabetes has been mandatory since November 2023, when the other conditions from the original notice were withdrawn (ePreskripce, in Czech). That condition is specific to that product.

No equivalent notice has been issued for Mounjaro. The other mechanism limiting who may prescribe, the restriction marked with the symbol L, is attached by SÚKL in a reimbursement decision and so reaches only medicines paid fully or partly from public insurance; since July 2024 even those may be prescribed by a general practitioner unless the product documentation says otherwise (ePreskripce, in Czech). Weight-management treatment is not reimbursed here, so that restriction does not attach either. A licensed Czech doctor may therefore prescribe within the authorised indication after assessing the patient. That is clinical judgement rather than paperwork: the doctor weighs the criteria, your history and your risks, and decides. A factual comparison of the products in this class, limitations included, is in GLP-1 medicines compared.

The weekly KwikPen and how titration works

In Czech pharmacies it comes in a multi-dose pre-filled KwikPen holding four weekly doses, so one pen covers roughly a month. Dosing follows the summary of product characteristics and how well you tolerate treatment:

Start: 2.5 mg once weekly for four weeks. This is an introductory dose for tolerability, not a treatment dose.
First increase: to 5 mg once weekly after four weeks.
Further titration: in 2.5 mg steps, never sooner than four weeks on the current dose.
Maintenance: 5 mg, 10 mg or 15 mg, with 15 mg once weekly the maximum.

Slow titration limits gastrointestinal side effects, and the doctor sets the target dose by effect and tolerability, so not everybody ends up on the highest. Needles are not included and are bought separately; an unopened pen is stored at 2–8 °C, and once in use it can be kept at up to 30 °C and must be discarded 30 days after first use. A missed dose can be taken within four days; after that, skip it and continue on the usual day, never doubling up.

What the clinical trials showed

In SURMOUNT-1, a trial in 2,539 adults with obesity or overweight and without diabetes, participants lost on average 15.0% of body weight at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, compared with 3.1% on placebo, with all groups also changing diet and physical activity (NEJM).

Those averages need two qualifications. Individual response varies substantially, and a proportion of participants lose considerably less or stop altogether, so a trial mean is not a result anyone can be promised. And the effect is tied to continuing treatment: in the SURMOUNT-4 withdrawal trial, participants who stopped regained a large share of the weight lost (JAMA). This is why obesity is managed as a chronic condition, with the end of treatment planned rather than improvised.

How the assessment works, and who decides

Whether any of this applies to you is not something an article can establish. The assessment looks at your BMI, weight-related conditions, medical history, the medicines you already take and what you want to achieve. The doctor weighs benefits against risks and decides. In a meaningful number of cases that decision is that treatment is not appropriate and should not be started. Our BMI calculator gives you one input for that conversation, nothing more.

A registered Czech GP is not a prerequisite, which matters when roughly 360,000 foreigners here have none (expats.cz); the route without one is described in obesity treatment in Czechia without a GP. At GoOn you complete an online questionnaire, then meet a licensed Czech doctor over video in English, with no surcharge for the language. If treatment is judged appropriate, the doctor issues a native Czech eRecept that you collect at any pharmacy; nothing is posted to you, since mail-order dispensing of prescription medicines is illegal in Czechia. Talk to a doctor online about your options.

Side effects and contraindications

Gastrointestinal effects are very common: nausea, diarrhoea and vomiting, with constipation and reduced appetite also frequent. They cluster around dose increases and usually ease over time, but can cause dehydration, so fluid intake matters. Cases of acute pancreatitis have been reported with tirzepatide, and combined with insulin or sulfonylureas the risk of hypoglycaemia rises. The medicine must not be used in case of hypersensitivity to the active substance or excipients, and caution applies to severe gastrointestinal disease and diabetic retinopathy, among others. It is not recommended in pregnancy; women of childbearing potential should use contraception and stop at least one month before a planned pregnancy. The full list is in the product information via EMA and SÚKL. A doctor makes the final decision on suitability.

Cost and reimbursement in Czechia

Pharmacotherapy for obesity is not covered by Czech public health insurance, so the medicine is self-paid, as it is for the estimated 60,000 to 80,000 people in the country funding this treatment themselves (Zdravotnický deník, March 2026). This applies identically to Czech nationals and foreign residents. The comprehensive foreigner policies sold here define their scope by reference to Czech public health insurance (PVZP, in Czech), and these medicines are not publicly reimbursed for anyone, so there is no foreigner surcharge and no separate foreigner pricing. Some Czech insurers do run prevention funds that may contribute towards weight-management programmes; the conditions change yearly, so check your own insurer's current terms. The pharmacy price depends on the product and the dose, so the monthly cost changes during titration. The full picture, consultations included, is in what weight-loss treatment costs in Czechia and Czech health insurance and weight-loss medication. Availability of individual strengths has varied over time; a pharmacy can confirm stock or order a pack in, as explained in GLP-1 availability in Czech pharmacies.

Practical notes for foreigners living in Czechia

An eRecept can be issued without a Czech insurance number, because the patient identifier can be your name and date of birth. The friction point is the counter: the routine ID-card lookup does not work for non-residents, so you need the prescription code itself, by SMS or printout. Cross-border acceptance of foreign e-prescriptions here is only partial, as just a subset of pharmacies participates (ePreskripce, in Czech), which is why a natively issued Czech prescription is the more reliable option for residents. Details are in our guide to the Czech eRecept and, for people arriving mid-treatment, continuing GLP-1 treatment after moving to Czechia.

Frequently asked questions

Who can prescribe Mounjaro in the Czech Republic?

For the weight-management indication, any licensed Czech doctor may prescribe after assessing the patient. Mounjaro has no product-specific eRecept notice of the kind published for the diabetes product Ozempic (ePreskripce, in Czech), and the L prescribing restriction reaches only medicines reimbursed from public health insurance (ePreskripce, in Czech). The decision is clinical, and the doctor may conclude treatment is not suitable.

How is Mounjaro prescribed in Prague and other Czech cities?

The process is the same nationwide: a medical assessment, then an eRecept if the doctor judges treatment appropriate, then collection at a pharmacy. Location affects only where you collect it, since an eRecept can be dispensed at any Czech pharmacy. Prescription medicines are never sent by post here.

Is Mounjaro covered by Czech health insurance?

No. Medicines used for weight management are not reimbursed from public health insurance in Czechia, so patients pay the pharmacy price themselves, regardless of nationality (Zdravotnický deník, March 2026). Some insurers run prevention funds that may contribute towards weight-management programmes, on terms that change yearly.

What happens if treatment is stopped?

Withdrawal data show that a large proportion of lost weight tends to return once treatment ends (JAMA). The exit strategy, whether continued treatment, a different approach or structured follow-up, is worth discussing with your doctor before starting rather than afterwards.